$0.182
-0.063 (-34.95%)Zum Schluss
- High
- 0.237
- Open
- 0.218
- VWAP
- 0.20
- Vol
- 23.47M
- Mkt Cap
- 82.99M
- Low
- 0.172
- Amount
- 4.62M
- EV/EBITDA, TTM
- 0.08
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Analyst Ratings (7)
Leerink
$5
2025-05-13
Leerink
2025-05-13
Kursziel
$5
Wells Fargo
$11
2025-05-13
Wells Fargo
2025-05-13
Kursziel
$11
Wells Fargo
$15
2024-12-12
Wells Fargo
2024-12-12
Kursziel
$15
HC Wainwright & Co.
$10
2024-12-10
HC Wainwright & Co.
2024-12-10
Kursziel
$10
Cantor Fitzgerald
—
2024-11-19
Cantor Fitzgerald
2024-11-19
Kursziel
—
Bewertungskennzahlen
Event-Zeitleiste
News
9.008-04GlobenewswireAffimed's New Therapy Shows High Efficacy in Relapsed Hodgkin Lymphoma
3.005-20TipRanks3 Penny Stocks to Watch Now, 5/20/25
2.005-19BenzingaDow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings
9.005-19BenzingaWhy Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
4.505-16BenzingaUS Stocks Edge Higher; Consumer Sentiment Falls In May
AFMD FAQ — answered by Alphio AI
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover AFMD: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 0.39.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.